CHRS Coherus BioSciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CHRS

Price (delayed)

$2.3

Market cap

$256.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.62

Enterprise value

$650.09M

Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings ...

Highlights
Coherus BioSciences's EPS has increased by 27% YoY and by 21% QoQ
The net income is up by 22% YoY and by 18% from the previous quarter
The equity has contracted by 38% YoY but it has grown by 24% from the previous quarter
The gross profit has grown by 35% from the previous quarter but it has contracted by 28% YoY
Coherus BioSciences's quick ratio has decreased by 34% YoY and by 14% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.coherus.com/
Peers: AGEN AMGN RGEN ACOR

Key stats

What are the main financial stats of CHRS
Market
Shares outstanding
111.36M
Market cap
$256.14M
Enterprise value
$650.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.08
Earnings
Revenue
$211.07M
EBIT
-$178.18M
EBITDA
-$172.39M
Free cash flow
-$261.47M
Per share
EPS
-$2.62
Free cash flow per share
-$2.68
Book value per share
-$1.41
Revenue per share
$2.16
TBVPS
$5.5
Balance sheet
Total assets
$583.78M
Total liabilities
$717.38M
Debt
$474.21M
Equity
-$133.6M
Working capital
$204.71M
Liquidity
Debt to equity
-3.55
Current ratio
1.85
Quick ratio
1.45
Net debt/EBITDA
-2.29
Margins
EBITDA margin
-81.7%
Gross margin
58%
Net margin
-102.9%
Operating margin
-88%
Efficiency
Return on assets
-44.8%
Return on equity
N/A
Return on invested capital
-24.8%
Return on capital employed
-51.8%
Return on sales
-84.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CHRS stock price

How has the Coherus BioSciences stock price performed over time
Intraday
7.98%
1 week
11.65%
1 month
-28.13%
1 year
-65.62%
YTD
-70.96%
QTD
-38.5%

Financial performance

How have Coherus BioSciences's revenue and profit performed over time
Revenue
$211.07M
Gross profit
$122.45M
Operating income
-$185.79M
Net income
-$217.11M
Gross margin
58%
Net margin
-102.9%
The gross profit has grown by 35% from the previous quarter but it has contracted by 28% YoY
The company's operating margin rose by 32% QoQ and by 14% YoY
The net margin has grown by 29% since the previous quarter and by 12% year-on-year
The operating income has grown by 24% YoY and by 21% from the previous quarter

Growth

What is Coherus BioSciences's growth rate over time

Valuation

What is Coherus BioSciences stock price valuation
P/E
N/A
P/B
N/A
P/S
1.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.08
Coherus BioSciences's EPS has increased by 27% YoY and by 21% QoQ
The equity has contracted by 38% YoY but it has grown by 24% from the previous quarter
The P/S is 79% below the 5-year quarterly average of 4.7 and 59% below the last 4 quarters average of 2.4
The revenue rose by 16% since the previous quarter but it has declined by 12% year-on-year

Efficiency

How efficient is Coherus BioSciences business performance
CHRS's return on invested capital is up by 46% year-on-year and by 25% since the previous quarter
Coherus BioSciences's return on sales has increased by 33% QoQ and by 19% YoY
The return on assets is up by 19% since the previous quarter and by 4.7% year-on-year

Dividends

What is CHRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CHRS.

Financial health

How did Coherus BioSciences financials performed over time
The total assets is 19% less than the total liabilities
Coherus BioSciences's quick ratio has decreased by 34% YoY and by 14% QoQ
The current ratio has contracted by 29% YoY and by 19% from the previous quarter
The equity has contracted by 38% YoY but it has grown by 24% from the previous quarter
The debt to equity has contracted by 31% from the previous quarter but it has grown by 28% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.